Your AI-Trained Oncology Knowledge Connection!
News
Video
Author(s):
Key opinion leaders address the treatment of recurrent or relapsed high-risk neuroblastoma, emphasizing the efficacy of antibody therapies naxitamab and dinutuximab, which target neuroblastoma cells, and the significance of post-induction therapy to enhance patient outcomes before transplantation.
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 19th 2025 - Jul 25th 2025
Jun 18th 2025 - Jun 19th 2026
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Jun 19th 2025 - Jul 25th 2025
Jun 18th 2025 - Jun 19th 2026
Jun 6th 2025 - Jul 12th 2025
Jun 6th 2025 - Jul 12th 2025
Jun 5th 2025 - Jul 12th 2025
Final PICCOLO Data Underscore Mirvetuximab Soravtansine’s Efficacy in Later-Line Frα+ Platinum-Sensitive Ovarian Cancer
First-Line Rucaparib Maintenance Reduces Progression Risk Across Prognostic Subgroups in HRD– High-Grade Ovarian Cancer
Raludotatug Deruxtecan Shows Activity in Platinum-Sensitive Ovarian Cancer
Relacorilant/Nab-Paclitaxel Is Associated With Survival Improvement in Platinum-Resistant Ovarian Cancer After Short Platinum-Free Interval
2 Commerce Drive
Cranbury, NJ 08512